The FDA and HHS are launching a Fast IND Pilot Program to prevent the outflow of early-stage drug development to overseas clinical trials.
The Crisis of U.S. Clinical Trial Outflow and the Development of Countermeasures
Recently, multinational pharmaceutical companies have been increasingly shifting their First-in-Human (FIH) trials to countries like Australia and Europe to avoid the stringent initial Investigational New Drug (IND) regulations and lengthy waiting times of the U.S. FDA. Australia's Clinical Trial Notification (CTN) system allows for rapid approval in approximately 4-6 weeks, which is more advantageous than the 30-day waiting period in the U.S. In response, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) launched 'Operation TrialBlazer' in June to restore global healthcare leadership and initiated regulatory innovation. The core of this initiative is the 'Expedited IND Pilot Program' announced recently.
Introduction of a Pre-Review System through Partnerships with Qualified Research Institutions (QRIs)
The key mechanism of this Fast IND Pilot Program is close collaboration between sponsors and Qualified Research Institutions (QRIs). QRIs, composed of university medical centers and major Contract Research Organizations (CROs), will conduct joint pre-reviews of non-clinical, clinical protocol, and Chemistry, Manufacturing, and Controls (CMC) data before IND submission. In particular, the introduction of a Rolling IND Submission platform will allow for the phased upload of clinical data and feedback, significantly reducing the occurrence of clinical holds.
Improving Funding Flow and Providing Opportunities to Demonstrate Corporate Value for Early-Stage Biotechs
The introduction of this pilot program provides a significant boost to early-stage biotech companies that urgently need funding and technology transfer (Licensing-out). Early-stage biotechs with low cash flow face significant pressure if clinical entry is delayed by several months, but early entry into Phase 1 trials through the Fast IND program allows them to quickly demonstrate their value. The faster re-evaluation of the value of high-risk, early-stage pipelines will facilitate subsequent investment from venture capital (VC) firms and the establishment of early partnerships.
Gathering Industry Opinions and Finalizing Future Roadmaps
The FDA is currently in the process of actively gathering diverse opinions from stakeholders to finalize the detailed design of this innovative program. The informational webinar held on August 6 was designed to inform stakeholders about the specific purpose of the program and encourage feedback, with a deadline for submitting comments of August 24. The industry is actively discussing various practical issues, such as the qualifications of QRIs and the allocation of legal responsibilities. After the deadline for submitting comments, the FDA plans to select up to 10 programs for a pilot project by the end of the year and begin actual operation.
This FDA's proposed Fast IND Pilot Program is a core component of the 'Operation TrialBlazer' policy promoted by the U.S. Department of Health and Human Services (HHS), and it will serve as an opportunity to prevent the outflow of early-stage (Phase 1) clinical trials to competing regions such as Australia and strengthen the U.S.'s global leadership. In the global early-stage clinical outsourcing market, which is expected to grow from approximately USD 9.5 billion in 2025 to USD 16.2 billion in 2035, the U.S. aims to secure its pipeline supply rights through regulatory innovation. In the short term, the demand for services from U.S.-based Qualified Research Institutions (QRIs), such as CROs and university hospitals, will expand, and companies will be able to proactively reduce the risk of clinical holds through Rolling Submissions. In particular, as the FDA plans to select up to 10 pilot programs for full-scale operation by the end of 2026, global pharmaceutical companies are urged to establish partnerships with U.S.-based CROs and revise their clinical design strategies.